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Cushing's Disease: Dilemmas of Diagnosis and Management
M. Saeed-uz-Zafar, MD,* Raymond C. Mellinger, MD,* and Max Wisgerhof, MD*

Determining the cause 1Jj" Cus!ting's disease and correcting the ahnormality presents a continuing
challenge to the clinician despite remar/.:ahle admnces in diagnos1ic and 1herapelllic techniques.
We present se,·en cases to i/lustraTe I) the classic disorder cured hy pituitary adenomectomy: 2)
persistence of the disease ajier adenomectomv; 3) Cushi11g·s disease manifesting in the puerperium
and remilling with dopamine agonist therapv; 4) a p(//ient whose disease relapsed at least ji,·e times
during 20 years ol treatme/11 hy adre11a/ectomy. pituitary radiation. mitotane. and pilllitary
adenomectomy: 5) the Nelson syndrome; 6) the ectopic adrenocorticotropic hormone (ACTH)
syndrome in a patient with dexamethasone suppressihle urinary cortisol who had a pituitary adenoma
which stained positi,·ely for ACTH hut who was 1101 rnred hy total hypophysecwmy: and 7) a patiem
whose ACTH-secreting tumor prm·ed fatal despite repeated surgical. radiologic. and pharmaco/ogic
measures. (Henry Ford Hosp Med J 1991 :39:10-17)

H

arvey Cushing first described a patient with this disorder in
1912 (I). Twenty years later he reviewed the features of
similar reported cases, some of whom were found at autopsy to
have basophilic adenomas of the pituitary. He proposed that this
pluriglandular disorder resulted from hyperfunction of pituitary
basophil adenoma (2). Although understanding of the patho
genesis, diagnosis, and therapy of Cushing's disease advanced
greatly over the next five decades. dilemmas persist. A condi
tion similar to Cushing's disease can be produced by nodular or
neoplastic disease of the adrenal glands as well as by tumors, be
nign or malignant, arising from either adrenal or pituitary tissue.
Development of a reliable adrenocorticotropic hormone (ACTH)
assay provides a ready demonstration when the disorder arises
from the adrenal glands, for the ACTH levels are very low.
However, in the presence of normal or elevated ACTH levels.
the clinician is frequently challenged to identify the source of
the hormone which is primarily responsible for the syndrome.
Despite new techniques to measure pituitary and adrenal hor
mones and advances in radiological methods to study the two
glands, the ultimate cause may defy detection and not be re
vealed even at autopsy (3). We present the details of seven pa
tients with ACTH-dependent Cushing's syndrome to illustrate
the dilemmas of diagnosis and management encountered in over
150 similar patients treated at this institution in the last five dec
ades.

dom plasma cortisol was 797 nmol/L (28.9 µg/dL) and the morning fol
lowing administration of I mg of dexamethasone the level was 830
nmol/L (30.1 µg/dL). Plasma ACTH concentration was 18 pmol/L (81
pg/mL) when cortisol was 847 nmol/L (30.7 µg/dL). Twenty-four hour
urinary cortisol was 549 nmol ( 199 µg). Administration of 8 mg of
dexamethasone at night resulted in a decline in plasma cortisol to 143
nmol/L (5.2 µg/dL) and ACTH to less than 2 pmol/L (< 8 pg/mL) the
next morning. Although the diagnosis of Cushing's disease seemed es
tablished, computed tomography (CT) of the sella turcica revealed no
abnormality. On the strength of the clinical data, transsphenoidal pitu
itary surgery was recommended and a microadenoma successfully re
moved. Two days after surgery plasma cortisol was 55 nmol/L (2 µg/
dL), and glucocorticoid therapy was required for the subsequent six
months of gradual clinical improvement. The removed pituitary tissue
stained heavily with ACTH antibody.

Comment

Classic Cushing's Disease

Harvey Cushing noted basophilic pituitary adenomas at au
topsy in six of eight patients with this disease and proposed that
these tumors were in some fashion the ultimate cause of the
hypercortisolism (2). Although the pathogenesis of pituitary
ACTH hypersecretion is still incompletely understood, there is
no dispute regarding the central role of the pituitary adenoma.
The majority of these tumors are small, do not enlarge the sella,
and may be difficult to detect before surgery by currently avail
able radiological techniques. Even employing the technique of
magnetic resonance imaging (MRI), no more than two-thirds of
the tumors can be demonstrated (4-8). Absence of radiologic ev-

Over the space of a few years a 75-year-old retired nurse developed
facial rounding, centripetal obesity, and multiple ecchymoses. She no
ticed gradual darkening of her skin, emotional ]ability. somnolence.
and lethargy, but increasing muscle weakness prompted her to seek
medical advice. The clinical diagnosis was Cushing's syndrome. Ran-
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idence of pituitary tumor in patients who have Cushing's syn
drome with elevated ACTH levels raises the difficult diagnostic
dilemma of the ectopic ACTH syndrome. Under these circum
stances, the 8 mg dexamethasone suppression test originally de
scribed by Liddle (9) to identify patients with Cushing's disease
is usually, but not always, completely reliable (I 0). In our expe
rience with problematic patients, the most promising procedure
to distinguish Cushing's disease from the ectopic ACTH syn
drome is the measurement of the ACTH response to cortico
tropin-releasing hormone (CRH), especially when petrosal si
nus and peripheral venous samples are compared. Determining
the serum cortisol response is reported to be additionally infor
mative (11,12).

Cushing's Disease Persistent
After Pituitary Adenomectomy
Case Report

A 30-year-old black female first seen in 1981 had a one-year history
of hypertension, diabetes. amenorrhea. and weight gain. She had no
ticed multiple ecchymoses, increasing pigmentation over her knuckles,
and supraclavicular fullness. Blood pressure was 170/100 mm Hg.
Plasma cortisol was elevated ( 966 nmol/L l35 µg/dL]) but urinary cor
tisol was only 276 nmol/d ( I 00 µg/24 hrs). Plasma cortisol the morning
after administration of I mg of dexamethasone was 33 I nmol/L ( 12 µg/
dL). The diagnosis of Cushing's disease was thought likely, but the pa
tient was lost to follow-up for two years. Seen again in 1983 because of
increasing muscle weakness, her plasma cortisol was high both in the
morning ( 1.186 nrnol/L [43 µg/dLJ) and afternoon (1,297 nrnol/L l47
µg/dLJ). Urinary cortisol had risen to 3.863 nmol/d ( 1.400 µg/24 hrs)
and plasma ACTH was 33 pmol/L ( 152 pg/mL). CT of the sella was re
ported as normal. After transsphenoidal adenomectomy plasma corti
sol declined to 152 nmol/L (5.5 µg/dL). The postoperative course was
complicated by pneumococcal meningitis treated successfully with in
travenous penicillin. Subsequently, the plasma cortisol value rose to
497 nmol/L ( 18 µg/dL) and the patient required no exogenous gluco
corticoids. Because the disease was believed not to have been cured. pi
tuitary radiation (5,000 rads) was administered and the patient treated
with mitotane. Early in 1984 she discontinued mitotane of her own vol i
tion and eight months later afternoon plasma cortisol level was 433
nmol/L (15.7 µg/dL). falling to 6 9 nmol/L (2.5 µg/dL) the morning af
ter I mg of dexamethasone.

Comment

The ability to identify intrasellar microadenomas and the de
velopment of microsurgical techniques revived transsphenoidal
pituitary surgery. Selective adenomectomy can be performed
leaving intact the normal pituitary tissue. Even when a pituitary
adenoma is not identified radiologically, if intrasellar ACTH
production appears certain, transsphenoidal removal of hyper
functioning tissue is usually curative (13-17). However, in a
substantial number of patients, when intrasellar lesions cannot
be identified and totally removed at surgery, ACTH hypersecre
tion persists. Such cases require subsequent total hypophysec
tomy, bilateral adrenalectomy, pituitary irradiation, or pharma
cologic therapy. In Cushing's disease the hypercortisolism is
the cause of morbidity and prompt correction is necessary. Al
though bilateral adrenalectomy usually achieves this end, subse-
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quent regrowth of adrenal remnants or the development of pitu
itary tumors are possible late complications.
In the reported patient transsphenoidal surgery was under
taken despite the absence of radiologic evidence of pituitary
neoplasm. Although the surgeon identified a pituitary adenoma
at surgery, its removal did not produce a cure and the patient de
veloped pneumococcal meningitis. Ultimately, a combination
of mitotane and pituitary irradiation corrected the hypercorti
solism. Very possibly, Cushing's disease in this patient could
have been managed primarily with a combination of mitotane
and external irradiation. However. reliable criteria are not yet
available to select such patients. Review of our total experience
with Cushing's disease suggests that patients whose urinary 17hydroxycorticosteroid levels fall more than 50% after admini
stration of 8 mg of dexamethasone are likely to respond well to
external irradiation.
Pituitary irradiation, once frequently used to treat this disor
der, is not often advised as primary therapy. Conventional ir
radiation involves administration of 4,400 to 5,000 rads but
complications increase with doses over 4.800 rads (18,19). Al
though biochemical and clinical improvement is frequently
achieved, the reported cure rate from radiation alone is only
15% to 25% in adults. Significant improvement is said to occur
in 80% of children treated (20) and when combined with unilat
eral adrenalectomy radiation therapy achieves a higher remis
sion rate at all ages (21). Conventional radiation requires about
18 months to attain its maximal effect. With special techniques
increased intensity of radiation can be delivered to the pituitary
(19). Radioactive gold or yttrium-90 implanted surgically by the
transsphenoidal approach produces a remission rate of 65% and
an additional 16% of patients are improved (22,23). However,
the frequency of operative complications is high and panhypo
pituitarism is commonly the ultimate result. Heavy particle irra
diation is frequently effective but is not widely available (24).
Reported side effects include temporary ocular motor distur
bance, visual loss, hypopituitarism, and secondary neoplasms
(25-27). Heavy particle therapy requires detailed knowledge of
the patient's sellar anatomy to guide the beam correctly, and sig
nificant extrasellar extension is a contraindication to its use (24 ).

Cushing's Syndrome Developing Postpartum
Case Report

A few days after term delivery. this 33-year-old white woman expe
rienced unexplained rectal hemorrhage. ln the following six weeks she
experienced emotional !ability, hyperkinesia, weakness, polydipsia,
and easy bruising. Referred with a diagnosis of fulminant Cushing's
syndrome possibly due to ectopic ACTH production, she was shown to
have plasma cortisol as high as 1,545 nmol/L (56 µg/dL) and urinary
cortisol of 2.83 I nmol/d (1,026 µg/24 hrs) but only minimally elevated
ACTH of 21 pmol/L ( 97 pg/mL). CT revealed pituitary enlargement.
After 8 mg of dexamethasone, urinary cortisol rose paradoxically to
6,896 nmol/d (2,500 µg/24 hrs). Pending etiologic diagnosis, admini
stration of aminoglutethimide lowered plasma cortisol to 35 9 nmol/L
( 13 µg/dL) but was discontinued because of scalp hair loss. Extensive
investigation failed to disclose any neoplastic disease, and the pituitary
was shown to be undergoing the expected postpartum involution. At
this point, therapeutic trial with bromocriptine, 7.5 µg/day. resulted in
normalization of plasma cortisol and symptomatic improvement. Inter-
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sue in six of 15 adenomas. These six subjects had hyperprolacti
nemia and responded to a single dose of bromocriptine with a
decline in prolactin as well as in ACTH levels, but cortisol levels
were not suppressed by administration of dexamethasone (30,
31 ). In the management of Cushing's disease, bromocriptine
therapy has produced variable results and responses are almost
always temporary (32,33). Although the disease results from
primary overactivity of the anterior pituitary, a functional ab
normality of the hypothalamus may be ultimately responsible in
some patients. Such cases may not be cured by transsphenoidal
hypophysectomy. A trial of bromocriptine therapy is recom
mended in selected patients, particularly those with associated
hyperprolactinemia, those whose cortisol is not suppressed with
high-dose dexamethasone, or those whose disease follows preg
nancy and delivery.
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Multiply Recurrent Cushing's Disease
Case Report
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Fig 1-LRvels of ACTH and cortisol during hromocriptine ad
ministration ro a patient with severe postpartum Cushing' s dis
ease. The remission has endured for over four years. (From
McKenna Ml, Linares M, Mellinger RC. Prolonged remission
of Cushing' s disease following hromocriptine therapy. Henry
Ford Hosp Med J 1987;35:188-91.)
ruption of the treatment three months later was followed by laboratory
and clinical recurrence, so bromocriptine administration was resumed.
During prolonged treatment, serum cortisol, ACTH, and urine corti ol
levels usually remained at normal concentrations. The patient was
symptomatically well except for four transient episodes of weight gain,
insomnia, and hyperactivity. During one of these episodes urinary cor
tisol was elevated, but the episodes resolved without adjustment of the
dose of bromocriptine (Fig I). Treatment was discontinued after 17
months and the patient has remained in remission for more than four
years. A detailed case report has been published (28).

Comment

Although pituitary hyperfunction is undoubtedly responsible,
this case raises the question of the pathogenetic mechanism for
the development of Cushing's disease postpartum and the prob
able roles played by the anterior and intermediate lobes as well
as the hypothalamus (29,30). The intermediate lobe, present in
rudimentary form during intrauterine life, involutes after birth.
However, these corticotroph cells may proliferate during preg
nancy. The cells process the ACTH precursor proopiomelano
cortin somewhat differently from the anterior lobe, have few re
ceptors for cortisol, but are inhibited by dopamine. Lamberts
and associates (31) provided evidence for the hypothesis that in
some patients Cushing's disease results from overactivity of the
intermediate lobe. Histologic studies with argyrophilic staining
of removed tissue have been interpreted as revealing neural tis-

12
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This 25-year-old widow was admitted to the hospital in 1969, fol
lowing a suicide attempt. Her emotional problems were said to have be
gun following her husband's murder three years earlier. Subsequently.
she gained weight and developed menstrual irregularities, high blood
pressure, and changes in body habitus. Laboratory data were consistent
with a diagnosis ofCushing's disease and in 1968 bilateral adrenalec
tomy was performed. Thereafter, she received glucocorticoid replace
ment therapy but was not clinically improved. One year later, after the
suicide gesture. she was referred to us. On admission, she had florid
features ofCushing's syndrome and the steroid therapy was withdrawn.
Plasma cortisol and urinary 17-hydroxycorticoid levels remained well
above the normal range. The patient was psychotically depressed and
required psychotropic drug therapy. Pituitary radiation was also admin
istered in a dose of 5,000 rads. Very little clinical improvement ensued
and plasma and urinary cortisol levels were well above normal a year
later. Therapy with mitotane (o,p'-DDD) 2 to 4 g daily was initiated in
June 1970.
During the next four years, two remissions, each lasting more than a
year, were induced by administration of the drug. During the fourth re
lapse of the disease, the patient experienced a violent headache and
nausea and vomiting which required hospitalization. Cushing 's disease
remitted again, pigmentation subsided, and the gonadotropins and thy
roid-stimulating hormone (TSH) became undetectable (34).
For the next 10 years the patient was physically and emotionally sta
ble receiving replacement doses of hydrocortisone, thyroxine, estro
gen, and progesterone. However, in A pril 1988, the hypercorticism re
curred yet again although other pituitary functions remained deficient.
A fter more than a year of variably effective medical management with
metyrapone, bromocriptine, and trifluoperazine hydrochloride, the pa
tient agreed to transsphenoidal hypophysectomy. A pituitary adenoma
was removed, and postoperatively ACTH was undetectable. The clini
cal remission still endures, but recent ACTH levels have again been
above the normal range. Chronology of this patient's course is shown in
the Table.

Comment

Before steroid replacement therapy became available, subto
tal adrenalectomy was the surgical treatment of choice for Cush
ing's disease, but high rates of either persistent and recurrent hy
percortisolism or fatal adrenal insufficiency prompted its aban
donment. Bilateral total adrenalectomy, possible after cortisone

Cushing·s Disease-Zafar et al

Table
Course of Multiply Recurrent Cushing's Disease
in a 25-Year-Old Woman
1968:
I 969:
1970:
1972:
1974:
1975:
1988:
1990:

Original diagnosis. Total adrenalectomy.
Persistent disease. Pituitary irradiation.
Persistent disease. Remission after mitotane therapy.
Relapse. Remission after mitotane therapy.
Relapse. Remission after mitotane therapy.
Relapse. Remission after pituitary apoplexy.
Relapse. Remission after transsphenoidal hypophysectomy.
? Relapse. Observation.

Note: The.most severe symptom, psychotic depression, characterized the disease, but
abated completely during the remissions.

became available for clinical use, corrected the hypercortisolism
but necessitated life-long steroid replacement (35.36). More
over, progressive hyperpigmentation with the development of a
pituitary tumor producing ACTH-the Nelson syndrome-was
reported in about I 0% of such patients (37). Persistent hypercor
tisolism following total adrenalectomy suggests incomplete re
moval of the adrenal glands. Persistent high ACTH levels stim
ulate any remaining adrenal tissue and may be sufficient to pro
duce a recurrence of the hypercortisolism (38,39). Remnant ad
renal tissue may represent incomplete surgical removal of hy
perplastic glands or activation of aberrant adrenal tissue. Acces
sory and ectopic adrenal cortical tissue has been reported by a
number of authors (40-42). Localization of functioning adrenal
remnants may be difficult, the most successful method being ra
dioactive iodocholesterol scanning (43-45).
This case of multiply recurrent Cushing's disease illustrates
the difficulties of therapy which characterize some patients. Bi
lateral adrenalectomy and subsequent pituitary radiation failed
to produce remission. In our experience either treatment is more
likely to fail if there has not been significant suppression of
steroid levels after administration of 8 mg of dexamethasone
orally. In the reported patient hypercortisolism was repeatedly
controlled with mitotane but the remissions were not perma
nent. The disorder was corrected for IO years after pituitary apo
plexy but ultimately surgical hypophysectomy was required.
Removal of the pituitary adenoma initially might well have been
the ideal approach although there is early evidence of still an
other recurrence.

The Nelson Syndrome
Case Report

A 25-year-old white woman was first treated for Cushing's disease
in 1953. Adrenal exploration revealed cortical hyperplasia, and she had
been treated with pituitary radiation, only 2,000 rads. Clinical remis
sion persisted until 1958 when a suspected relapse was confirmed and
she received an additional 1,500 rads. Because remission remained in
complete, bilateral adrenalectomy was performed in 1963. Despite re
placement glucocorticoid therapy, the patient became progressively
hyperpigmented and in 1967 had transient left third nerve palsy. She re
ceived a third course of pituitary irradiation and improved sufficiently
to continue with only conventional hydrocortisone therapy. By 1978,
hyperpigmentation was intense and ACTH concentration was I, 718
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pmol/L (7,800 pg/mL). CT disclosed an intrasellar mass which was re
moved by the transsphenoidal approach. ACTH level fell to 15 pmol/L
(67 pg/mL) postoperatively and the pigmentation diminished. In the
next two years ACTH again rose progressively to over 77 pmol/L
(> 350 pg/mL) and further pituitary surgery was performed. ACTH
concentration has remained normal since 1981.

Comment
In 1958 Nelson and colleagues (46) described a patient with a
large pituitary chromophobe adenoma which had developed in
the three years after bilateral adrenalectomy for Cushing's dis
ease. The patient had excessive pigmentation, amenorrhea, and
visual field impairment. ACTH levels which were markedly ele
vated did not decline normally after intravenous hydrocortisone
administration. The authors proposed that an ACTH-producing
tumor had developed in response to the lower cortisol levels
produced by bilateral adrenalectomy. Incidence of the Nelson
syndrome, diagnosis of which depends upon the criteria em
ployed, ranges between 5% to 78% (47-49). Inclusion of those
patients who have hyperpigmentation but no radiographic evi
dence of a pituitary tumor increases the incidence. The hyper
pigmentation and enlarging sellar mass may occur months to
years after adrenalectomy and ACTH levels may exceed 3,303
pmol/L (15,000 pg/mL) (37,50).
Previous pituitary irradiation does not prevent occurrence of
the Nelson syndrome. contrary to earlier concepts (5 I ,52). Gen
erally, the syndrome has a benign course characterized by hy
perpigmentation and slowly progressive changes in the sella tur
cica. However, some tumors are rapidly progressive, and su
prasellar extension compresses the optic nerves (53). Some have
even been considered malignant. Pituitary apoplexy occurs with
some frequency in these tumors, either spontaneously or in as
sociation with manipulative procedures (54).
Development of the Nelson syndrome after bilateral adre
nalectomy for Cushing's disease cannot be predicted reliably.
About 90% of the large pituitary tumors demonstrated either
at the time of diagnosis of Cushing's disease or after adrenal
ectomy are chromophobe adenomas. An occasional tumor is
found to be eosinophilic, but more sophisticated techniques
such as electron microscopy and immunohistochemistry con
firm that these tumors are composed of corticotroph cells (55).
Results of treatment of the Nelson syndrome, particularly i_n
those patients with large invasive tumors, are disappointing.
Conventional irradiation is effective in only a minority. Heavy
particle irradiation either with the proton beam or with alpha
particles is more effective but cannot be used to treat large tu
mors with extra sellar extension. Surgery, transsphenoidal or
transfrontal, is usually successful, but recurrences are common.
Response to administration of cyproheptadine. used in a few
cases, is variable and unpredictable. Abandonment of total adre
nalectomy as primary therapy for Cushing's disease in favor of
transsphenoidal adenomectomy may reduce the frequency of
the disorder. Patients who have undergone bilateral adrenalec
tomy should be monitored regularly by means of plasma ACTH
levels, visual field examinations, and MRI of the pituitary.
The described patient developed hyperpigmentation several
years after bilateral adrenalectomy. Prior pituitary irradiation

Cushing's Disease-Zafar et al
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(A)

(B)

Fig 2-Pituitary adenoma removed by transsphenoidal hypophysectomy. A) Hemato.xylin-eosin stain (x 100). B) lmmunoperoxi
dase stain confirming heavy concentration of ACTH. Removing the adenoma did not lower the plasma ACTH level nor alleviate
Cushing' s syndrome. After subsequent adrenalectomy, metastatic, ACTH-positive neuroendocrine tumor was demonstrated by liver
biopsy.

did not prevent the development of the symptomatic pituitary
tumor. Transsphenoidal removal of the pituitary tumor, per
formed twice, did not completely eliminate ACTH secretion and
mild hyperpigmentation persists.

Ectopic ACTH Production of Unknown Source
Case Report

A 23-year-old white woman was admitted to the hospital for man
agement of Cushing 's syndrome, symptoms of which had been present
for two years. Despite the presence of hypokalemia, hyperglycemia,
and high plasma cortisol (I,186 nmol/L [ 43 µg/dL]), the urinary corti
sol level was only slightly above normal (414 nmol/d [ 150 µg/24 hrs])
and declined to 22 nmol/d (8 µg/24 hrs) after administration of dexa
methasone, 2 mg four times a day for two days. Because the patient was
taking oral contraceptives to regulate her menses, the hypercortisol
emia was considered to be caused by increased cortisol binding globu
lin. However, a year later when she was not receiving estrogen, plasma
cortisol was 828 nmol/L (30 µg/dL) and was not reduced overnight by
I mg of dexamethasone (910 nmol/L (33 µg/dL]). Moreover. plasma
ACTH level was 61 pmol/L (276 pg/mL). Cerebral CT was interpreted
as demonstrating an intrasellar mass while chest x-ray was negative.
Transsphenoidal hypophysectomy produced no clinical or biochemical
improvement although the tissue removed stained heavily for ACTH
and the pathologic diagnosis was ACTH-secreting pituitary adenoma
(Fig 2). After surgery the ACTH level was 107 pmol/L (485 pg/mL).
CT of the chest and abdomen revealed no ectopic source for the ACTH
and reexploration of the sella yielded no additional tumor tissue al
though the pituitary remnant was removed. The patient became pro
gressively worse and was confined to bed with muscle weakness. A few
weeks after the second pituitary operation she developed meningitis
which responded to antibiotic therapy. Need to correct the progressive

14
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Fig 3-Patient after total hypophysectomy and adrenalectomy.
illness led to bilateral adrenalectomy with gratifying clinical results.
The patient's strength gradually returned, blood pressure became nor
mal, and she resumed her usual activity. A few months later, however,
she developed intense dermal pigmentation (Fig 3), and the ACTH
level had risen to 2,202 pmol/L ( I 0,000 pg/mL). Repe£1t CT of the ab
domen now demonstrated a hepatic defect. Tissue obtained by liver bi
opsy had features of a neuroendocrine tumor and stained intensely for
ACTH but not for CRF.

Comment
The most vexing problem facing the clinician is to differenti
ate excess ACTH of pituitary origin from one of ectopic source.
This phenomenon of ectopic ACTH production was one of the
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first humoral paraneoplastic syndromes described. In 1928, W.
Hurst Brown (56) reported a patient with oat cell carcinoma of
the lung who had clinical signs of hypercortisolism and was
found to have adrenal hyperplasia. Since then increasing num
bers of patients have been reported to have Cushing's syndrome
secondary to extra-endocrine benign or malignant tumors. Clin
ical manifestations vary. Glucose intolerance is frequent and
frank diabetes may occur. Weakness, hypokalemia, and weight
loss generally accompany the disorder. However, these features
are not unique to the ectopic ACTH syndrome and in some pa
tients the disorder closely mimics Cushing's disease.
Oat cell carcinoma of the lung is the neoplasm most com
monly responsible for this disorder. Other reported tumors in
clude thymoma, carcinoid (thymic, endobronchial, gastric, pan
creatic), medullary carcinoma of the thyroid, salivary gland tu
mors, ovarian cancer, islet cell carcinoma of the pancreas, mela
noma, pheochromocytoma, squamous cell carcinoma of the cer
vix, and carcinoma of the prostate (57-72). Some of these tu
mors have been reported to produce CRF in addition to ACTH
but its biologic significance is not completely understood (7376).
The hypercortisolism of ectopic ACTH syndrome usually
produces significant morbidity such as hyperglycemia, wasting,
weakness, and severe electrolyte disturbance. Although treat
ment which controls hypercortisolism may prolong life, the risk
of bilateral adrenalectomy is great for these seriously ill pa
tients, many of whom have malignant tumors. Pharmacologic
agents which inhibit adrenal secretion provide useful treatment
(77,78).
The reported patient demonstrates several problems in diag
nosis and management. The ectopic production of ACTH was
not recognized initially, and the location of the primary neo
plasm continues to evade us. The undoubted presence of a corti
cotrophic pituitary adenoma is additionally confounding. The
hypercortisolism was not corrected by removal of this adenoma
but only by bilateral adrenalectomy. Subsequent generalized
hyperpigmentation has been severe.

The Incurable Case
Case Report

A 33-year-old white pipe fitter was seen initially in 1975 with signs
and symptoms of Cushing ·s syndrome. He was mildly hyperpigmented
and his blood pressure was 170/100 mm Hg. Plasma cortisol level was
elevated and fell only to 535 nmol/L (19.4 µg/dL) the morning after ad
ministration of I mg of dexamethasone. Urinary 17-hydroxycorticos
teroids were also high and failed to decline after administration of 8 mg
of dexamethasone on each of two days ( 151 µmol/d [54.8 mg/24 hrs]).
ACTH level was 73 pmol/L (333 pg/mL). The diagnosis was Cushing's
disease, and 5,000 rads of cobalt radiation were administered to the pi
tuitary area while mitotane ( I to 4 g daily) was taken by mouth. Clinical
improvement was not sustained and two years later CT revealed a pitu
itary mass with suprasellar extension. Transsphenoidal hypophysec
tomy was performed in 1978. Histologic study revealed diffuse fibrosis
with degenerative changes of the pituitary but no tumor was found.
Nonetheless. after surgery cortisol therapy was required and ACTH re
mained at undetectable levels for about three years. In 1983 plasma cor
tisol concentrations rose again to 1 ,159 nmol/L (42 µg/dL) and mito
tane therapy was reinstituted. CT of the sella disclosed a recurrent pitu-
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itary mass. Pituitary tissue removed again by the transsphenoidal ap
proach revealed only fibrosis although the patient experienced postop
erative failure of both the gonadotropins and TSH. ACTH remained
high and the hypercortisolism was controlled with mitotane. Addi
tional radiation was administered but neither cyproheptadine or bro
mocriptine administration produced any observable effect.
By 1987, ACTH levels consistently exceeded 2,202 pmol/L ( I 0,000
pg/mL), the patient was intensely pigmented, and the pituitary tumor
had invaded the cavernous sinus and right orbit. A major but subtotal
excision was accomplished transcranially although the ACTH level re
mained over 1,321 pmol/L (6,000 pg/mL) and mitotane was required to
control the adrenal hyperfunction. The pituitary tumor continued to en
large and the patient died in 1991.

Comment
This case demonstrates that currently available methods to
treat Cushing's disease may be inadequate. This patient under
went "maximum" pituitary irradiation as well as four attempts at
surgical removal of the pituitary tumor. He remained uncured.
Mitotane administration controlled the glucocorticoid excess,
but huge excesses of ACTH were secreted by the devastating in
tracranial tumor.
In this patient urinary 17-hydroxycorticosteroids were not
suppressed by administration of 8 mg of dexamethasone before
he had received any therapeutic intervention. ln our experience
such data suggest a poor prognosis and aggressive surgical treat
ment should be undertaken at the outset.

Ii

Summary

Harvey Cushing's great contribution at the beginning of this
century was to establish the role of pituitary adenoma in the gen
esis of the disease that bears his name. Although the pituitary
adenoma is now clearly understood to be the cause of the classic
disorder, variable results of medical, radiologic, and surgical
treatment as well as the propensity to recurrence and invasion
make management a serious dilemma. Moreover, a clinically
similar disorder can be produced not only by hyperfunctioning
adrenal neoplasms but also by ACTH produced ectopically in a
variety of "nonendocrine" tumors. The true source of ACTH
hypersecretion, the incompletely understood involvement of the
hypothalamus, and the possible return of pituitary hyperfunc
tion after surgery are considerations which can confound the di
agnostician. Despite spectacular radiologic advances, imaging
studies can be misleading. We believe that of the currently avail
able diagnostic techniques, the measurement of ACTH gradient
in the petrosal sinuses and peripheral vein blood obtained simul
taneously after CRH administration is the most reliable means
of identifying the source of ACTH excess.
The success of therapy, which at best is unpredictable, de
pends first of all on accurate diagnosis of the disease. When
Cushing's disease is due to a pituitary adenoma, transsphe
noidal adenomectomy is often ideal treatment.
Recurrence of the disease after pituitary adenomectomy may
respond to irradiation. Despite a disappointing rate of remission,
radiotherapy should not be dismissed as primary therapy, espe
cially in conjunction with medical measures to control adrenal
hyperfunction. Neither should medical control of the pituitary
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gland be overlooked, especially in atypical cases such as the re
ported patient with puerperal onset of the disorder. Ectopically
secreted ACTH can mimic pituitary hyperfunction precisely or
coexist with it. In such cases, accurate preoperative diagnosis
may not be possible at the present time, and the ultimate source
of the disorder will continue to defy demonstration. Finally,
given the ability of the pituitary adenoma to recur and invade,
resisting all present measures to control the disease, some pa
tients with Cushing's disease will remain uncured and incur
able.
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